The most award winning
healthcare information source.
TRUSTED FOR FOUR DECADES.
HIV prevention in serodiscordant pair
By Dean L. Winslow, MD, FACP, FIDSA
Chief, Division of AIDS Medicine, Santa Clara Valley Medical Center; Clinical Professor, Stanford University School of Medicine
Dr. Winslow is a speaker for GSK and a consultant for Siemens Diagnostics.
Synopsis: A total of 1,763 couples serodiscordant for HIV-1 infection were enrolled in this prospective trial. HIV-1-infected patients with CD4+ lymphocyte counts between 350 and 500 cells/mL were randomized to receive either immediate therapy or have antiretroviral therapy deferred until either onset of HIV-related symptoms or decline in CD4+ count. At the time of this analysis, 39 HIV-1 transmissions were observed and 28 were virologically linked to the infected partner. Of these, only 1 occurred in the early therapy group..
Sources: Cohen MS, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011 July 18; Epub ahead of print
A total of 1,763 HIV-1 serodiscordant couples in nine countries with the infected partner having CD4+ counts of 350-500/mL were randomized 1:1 to early (immediate) vs. delayed (CD4+ had declined to ≤ 250/mL or after development of an AIDS-related illness) antiretroviral therapy of the infected partner. Fifty-four percent of the subjects were from Africa; 50% of the infected partners were men; 97% of couples were heterosexual; and 94% were married.
As of February 2011, after a median follow-up of 1.7 years, a total of 39 HIV-1 transmissions were observed. Sequencing of the pol genes from linked cases showed that 28 were virologically linked to the infected partner. Of these linked transmissions, only 1 occurred in the early therapy group. Early antiretroviral therapy also resulted in fewer primary clinical endpoints (occurrence of pulmonary TB, severe bacterial infections, a WHO stage 4 event or death) in the HIV infected partners.
This is a very important study, which conclusively shows that early initiation of antiretroviral therapy reduces transmission of HIV-1 in serodiscordant couples. Consistent with previous studies, high viral load at baseline predicted HIV-1 transmission. In the early treatment group, 89% of patients had plasma HIV RNA < 400 copies/mL after 3 months of treatment. The study has obvious direct relevance to HIV prevention efforts and, even in the absence of formal cost-benefit analyses, provides additional justification for universal implementation of early antiretroviral therapy in the developing world.